Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Protein Page:
SFRS9 (human)
p Phosphorylation
a Acetylation
m Methylation
m1 Mono-methylation
m2 Di-methylation
m3 Tri-methylation
u Ubiquitination
s Sumoylation
n Neddylation
g O-GlcNAc
h Palmitoylation
ad Adenylylation
sn S-Nitrosylation
ca Caspase cleavage

Overview
SFRS9 Plays a role in constitutive splicing and can modulate the selection of alternative splice sites. Represses the splicing of MAPT/Tau exon 10. Belongs to the splicing factor SR family. Note: This description may include information from UniProtKB.
Protein type: RNA binding protein; RNA splicing
Cellular Component: nucleoplasm; nucleolus; nucleus
Molecular Function: RNA binding; nucleotide binding
Biological Process: nuclear mRNA splicing, via spliceosome; transcription from RNA polymerase II promoter; mRNA splice site selection; mRNA export from nucleus; negative regulation of nuclear mRNA splicing, via spliceosome; RNA splicing; gene expression; mRNA 3'-end processing; mRNA processing; termination of RNA polymerase II transcription
Reference #:  Q13242 (UniProtKB)
Alt. Names/Synonyms: Pre-mRNA-splicing factor SRp30C; SFRS9; Splicing factor, arginine/serine-rich 9; SRP30C
Gene Symbols: SRSF9
Molecular weight: 25,542 Da
Basal Isoelectric point: 8.74  Predict pI for various phosphorylation states
Select Structure to View Below

SFRS9

Protein Structure Not Found.


STRING  |  Scansite  |  Phospho.ELM  |  NetworKIN  |  Pfam  |  DISEASE  |  Source  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene


Modification Sites and Domains Show Modification Legend
Click here to view phosphorylation modifications only

Modification Sites in Parent Protein, Orthologs, and Isoforms Show Modification Legend
 

Show Multiple Sequence Alignment


 SS 

SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 MS 

MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
0 2 S2-p ______MsGWADERG
0 3 Y17-p GEGDGRIyVGNLPTD
0 2 K28-u LPTDVREkDLEDLFy
0 2 Y35-p kDLEDLFykYGRIRE
0 10 K36-u DLEDLFykYGRIREI
0 109 Y70-p RDAEDAIyGRNGyDY
0 19 Y75-p AIyGRNGyDYGQCRL
0 3 R93-m1 FPRTYGGrGGWPrGG
0 1 R98-m1 GGrGGWPrGGRNGPP
0 3 K128-u SGSWQDLkDHMREAG
0 3 Y139-p REAGDVCyADVQkDG
0 1 K144-u VCyADVQkDGVGMVE
0 1 K155-u GMVEYLRkEDMEyAL
0 2 Y160-p LRkEDMEyALRKLDD
0 1 T168-p ALRKLDDtkFRSHEG
0 3 K169-u LRKLDDtkFRSHEGE
0 3 S178-p RSHEGETsyIRVYPE
0 51 Y179-p SHEGETsyIRVYPER
0 2 S187-p IRVYPERstsyGysR
0 1 T188-p RVYPERstsyGysRs
0 31 S189-p VYPERstsyGysRsR
0 1 Y190-p YPERstsyGysRsRs
0 4 Y192-p ERstsyGysRsRsGs
0 8 S193-p RstsyGysRsRsGsR
0 3 S195-p tsyGysRsRsGsRGR
0 7 S197-p yGysRsRsGsRGRDs
0 9 S199-p ysRsRsGsRGRDsPy
0 152 S204-p sGsRGRDsPyQsRGs
0 2 Y206-p sRGRDsPyQsRGsPH
0 12 S208-p GRDsPyQsRGsPHyF
0 339 S211-p sPyQsRGsPHyFsPF
0 130 Y214-p QsRGsPHyFsPFRPy
1 105 S216-p RGsPHyFsPFRPy__
0 5 Y221-p yFsPFRPy_______
  mouse

 
S3-p _____MSsGWADERG
Y18 GEGDGRIYVGNLPSD
K29 LPSDVREKDLEDLFY
Y36 KDLEDLFYkYGRIRE
K37-u DLEDLFYkYGRIREI
Y71-p RDAEDAIyGRNGYDY
Y76 AIyGRNGYDYGQCRL
R94 FPRTYGGRGGWPRGA
R99 GGRGGWPRGARNGPP
K129 SGSWQDLKDHMREAG
Y140 REAGDVCYADVQKDG
K145 VCYADVQKDGMGMVE
K156 GMVEYLRKEDMEYAL
Y161 LRKEDMEYALRKLDD
T169 ALRKLDDTKFRSHEG
K170 LRKLDDTKFRSHEGE
S179 RSHEGETSyIRVYPE
Y180-p SHEGETSyIRVYPER
S188 IRVYPERSTsYGysR
T189 RVYPERSTsYGysRs
S190-p VYPERSTsYGysRsR
Y191 YPERSTsYGysRsRs
Y193-p ERSTsYGysRsRsGs
S194-p RSTsYGysRsRsGsR
S196-p TsYGysRsRsGsRGR
S198-p YGysRsRsGsRGRDs
S200-p ysRsRsGsRGRDsPY
S205-p sGsRGRDsPYQsRGs
Y207 sRGRDsPYQsRGsPH
S209-p GRDsPYQsRGsPHyF
S212-p sPYQsRGsPHyFsPF
Y215-p QsRGsPHyFsPFRPY
S217-p RGsPHyFsPFRPY__
Y222 yFsPFRPY_______
  rat

 
S2 ______MSGWADERG
Y17 GEGDGRIYVGNLPTD
K28 LPTDVREKDLEDLFY
Y35 KDLEDLFYKYGRIRE
K36 DLEDLFYKYGRIREI
Y70 RDAEDAIYGRNGYDY
Y75 AIYGRNGYDYGQCRL
R93 FPRAYGGRGGWPRAS
R98 GGRGGWPRASRNGPP
K128 SGSWQDLKDHMREAG
Y139 REAGDVCYADVQKDG
K144 VCYADVQKDGMGMVE
K155 GMVEYLRKEDMEYAL
Y160 LRKEDMEYALRKLDD
T168 ALRKLDDTKFRSHEG
K169 LRKLDDTKFRSHEGE
S178 RSHEGETSYIRVYPE
Y179 SHEGETSYIRVYPER
G187 IRVYPERGTSYGCSR
T188 RVYPERGTSYGCSRS
S189 VYPERGTSYGCSRSR
Y190 YPERGTSYGCSRSRS
C192 ERGTSYGCSRSRSGS
S193 RGTSYGCSRSRSGSR
S195 TSYGCSRSRSGSRGR
S197 YGCSRSRSGSRGRDs
S199 CSRSRSGSRGRDsPY
S204-p SGSRGRDsPYQSRGs
Y206 SRGRDsPYQSRGsPH
S208 GRDsPYQSRGsPHYF
S211-p sPYQSRGsPHYFsPF
Y214 QSRGsPHYFsPFRPY
S216-p RGsPHYFsPFRPY__
Y221 YFsPFRPY_______
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.